Effect of Buprenorphine and Bupropion in the reduction of hashish craving
Not Applicable
Completed
- Conditions
- Cannabis Dependency.Mental and behavioural disorders due to use of cannabinoids
- Registration Number
- IRCT2016040525160N3
- Lead Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
Age between 18 to 50; They are free to participate in the study, patient's major substance use be cannabis
Exclusion criteria: Patients unwilling to participate at beginning or during the study, use of another substance except cannabis as of the main substance.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Craving. Timepoint: daily for 2 weeks. Method of measurement: questionnaire and interview.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the anti-craving effects of buprenorphine and bupropion in cannabis use disorder?
How does the combination of buprenorphine and bupropion compare to standard-of-care treatments for cannabis dependency in clinical trials?
Are there specific biomarkers that predict response to buprenorphine or bupropion in reducing cannabis craving?
What are the potential adverse events associated with buprenorphine and bupropion in cannabis use disorder treatment?
What other pharmacological agents or combination therapies are being explored for managing cannabinoid-induced mental and behavioural disorders?